Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Molecular Biomarkers in Cardiovascular Disease

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Benefits of Publishing in a Special Issue
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 15695

Share This Special Issue

Special Issue Editors

Prof. Dr. Sanja Stankovic

E-Mail Website
Guest Editor

1. Centre for Medical Biochemistry, University Clinical Centre of Serbia, 11000 Belgrade, Serbia
2. Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
Interests: biomarkers in cardiovascular disease; public health; pharmacogenomics; TBI biomarkers; automation; healthcare management
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Antoni Bayés-Genís

E-Mail Website
Guest Editor

Hospital Univeersitari Germans Trias I Pujol, Universitat Autonima Barcelona, 08916 Badalona, Spain
Interests: biomarkers in CV disease; heart failure; cardiac rejuvenation

Special Issue Information

Dear Colleagues,

In recent years, the incidence and onset age of cardiovascular disease have advanced. Cardiovascular disease has become an important problem for cardiovascular health. In order to strengthen the prevention and treatment of cardiovascular diseases, this Special Issue “Molecular Biomarkers in Cardiovascular Disease” welcomes original research articles, reviews, methods, and other article types focused on (but not limited to) the following areas:

Cardiovascular disease;
Biomarkers;
Heart failure;
Takayasu arteritis;
Vasculitis;
Vascular damage;
Diagnosis;
Therapy.

Dr. Sanja Stankovic
Prof. Dr. Antoni Bayés-Genís
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2062 KiB

Open AccessArticle

Exploring Novel Biomarkers for an Acute Coronary Syndrome Diagnosis Utilizing Plasma Metabolomics

by Masayuki Shibata, Masahiro Sugimoto, Norikazu Watanabe and Atsuo Namiki

Int. J. Mol. Sci. 2024, 25(12), 6674; https://doi.org/10.3390/ijms25126674 - 18 Jun 2024

Viewed by 1029

Abstract

Acute coronary syndrome (ACS) is a life-threatening condition that requires a prompt diagnosis and therapeutic intervention. Although serum troponin I and creatinine kinase-MB (CK-MB) are established biomarkers for ACS, reaching diagnostic values for ACS may take several hours. In this study, we attempted to explore novel biomarkers for ACS with higher sensitivity than that of troponin I and CK-MB. The metabolomic profiles of 18 patients with ACS upon hospital arrival and those of the age-matched control (HC) group of 24 healthy volunteers were analyzed using liquid chromatography time-of-flight mass spectrometry. Volcano plots showed 24 metabolites whose concentrations differed significantly between the ACS and HC groups. Using these data, we developed a multiple logistic regression model for the ACS diagnosis, in which lysine, isocitrate, and tryptophan were selected as minimum-independent metabolites. The area under the receiver operating characteristic curve value for discriminating ACS from HC was 1.00 (95% confidence interval [CI]: 1.00–1.00). In contrast, those for troponin I and CK-MB were 0.917 (95% confidence interval [CI]: 0.812–1.00) and 0.988 (95% CI: 0.966–1.00), respectively. This study showed the potential for combining three plasma metabolites to discriminate ACS from HC with a higher sensitivity than troponin I and CK-MB. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Figure 1

13 pages, 1129 KiB

Open AccessArticle

Inflammatory Cytokines Are Associated with Cognitive Dysfunction and Depressive State during Acute Bacterial Infections and the Recovery Phase

by Mónica Arias-Colinas, Alfredo Gea, Ahmed Khattab, Michael Vassallo, Stephen C. Allen and Joseph Kwan

Int. J. Mol. Sci. 2023, 24(18), 14221; https://doi.org/10.3390/ijms241814221 - 18 Sep 2023

Viewed by 1233

Abstract

During a bacterial infection, individuals may present with behavioral changes referred to as sickness behavior, which has been suggested is induced by the inflammatory markers that are released because of the infective immunological challenge. However, few studies have explored this multidimensional phenomenon in naturally occurring conditions. A longitudinal observational study was conducted to explore the role of inflammatory cytokines in mediating the sickness behavior during a bacterial infection. There were 13, 11 and 37 participants in the infection, hospital control and healthy groups, respectively. They were all followed up for 6 weeks and their inflammatory markers were quantified throughout those weeks. Cognitive function and depressive state were assessed by means of the Mini-Mental State Examination (MMSE) and Cornell Scale for Depression in Dementia (CSDD). Reductions in proinflammatory markers C-Reactive protein (CRP), interleukin – 6 (IL6) and tumor necrosis factor-α (TNFα) and increments in anti-inflammatory markers (interleukin – 4 (IL4)) were associated with an improvement in CSDD and MSEE in patients recovering from a bacterial infection. The correlation between inflammatory makers and CSDD was statistically significant for the CRP (r = 0.535, p = 0.001), the IL6 (r = 0.499, p < 0.001), the TNFα (r = 0.235, p = 0.007) and the IL4 (r = −0.321, p = 0.018). Inflammatory cytokines may mediate sickness behavior during acute illness. These results may enhance the understanding of the pathophysiology and potential treatment strategies to palliate this sickness behavior. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Figure 1

16 pages, 1866 KiB

Open AccessArticle

Does Albumin Predict the Risk of Mortality in Patients with Cardiogenic Shock?

by Tobias Schupp, Michael Behnes, Jonas Rusnak, Marinela Ruka, Jonas Dudda, Jan Forner, Sascha Egner-Walter, Max Barre, Mohammad Abumayyaleh, Thomas Bertsch, Julian Müller and Ibrahim Akin

Int. J. Mol. Sci. 2023, 24(8), 7375; https://doi.org/10.3390/ijms24087375 - 17 Apr 2023

Cited by 7 | Viewed by 1691

Abstract

This study investigates the prognostic impact of albumin levels in patients with cardiogenic shock (CS). Intensive care unit (ICU) related mortality in CS patients remains unacceptably high despite improvement concerning the treatment of CS patients. Limited data regarding the prognostic value of albumin in patients with CS is available. All consecutive patients with CS from 2019 to 2021 were included at one institution. Laboratory values were retrieved from the day of disease onset (day 1) and days 2, 3, 4, and 8 thereafter. The prognostic impact of albumin was tested for 30-day all-cause mortality. Moreover, the prognostic performance of albumin decline during ICU treatment was examined. Statistical analyses included univariable t-test, Spearman’s correlation, Kaplan–Meier analyses, multivariable mixed analysis of variance (ANOVA), C-Statistics, and Cox proportional regression analyses. In total, 230 CS patients were included, with an overall all-cause mortality at 30 days of 54%. The median albumin on day 1 was 30.0 g/L. Albumin on day 1 was able to discriminate between 30-day survivors and non-survivors (area under the curve (AUC) 0.607; 0.535–0.680; p = 0.005). CS patients with albumin < 30.0 g/L were associated with an increased risk of 30-day all-cause mortality (63% vs. 46%; log-rank p = 0.016; HR = 1.517; 95% CI 1.063–2.164; p = 0.021), which was demonstrated even after multivariable adjustment. Moreover, a decrease of albumin levels by ≥20% from day 1 to day 3 was accompanied by a higher risk of 30-days all-cause mortality (56% vs. 39%; log-rank p = 0.036; HR = 1.645; 95% CI 1.014–2.669; p = 0.044). Especially when combined with lactate, creatinine, and cardiac troponin I, reliable discrimination of 30-day all-cause mortality was observed, including albumin in CS risk stratification models (AUC = 0.745; 95% CI 0.677–0.814; p = 0.001). In conclusion, low baseline albumin levels as well as a decay of albumin levels during the course of ICU treatment, deteriorate prognostic outcomes in CS patients. The additional assessment of albumin levels may further improve risk stratification in CS patients. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Figure 1

15 pages, 4801 KiB

Open AccessArticle

Exploring Potential Biomarkers and Molecular Mechanisms of Ischemic Cardiomyopathy and COVID-19 Comorbidity Based on Bioinformatics and Systems Biology

by Simin Luo, Xuan Zhang, Xiang Xiao, Wenting Luo, Zixuan Yang, Songqi Tang and Wei Huang

Int. J. Mol. Sci. 2023, 24(7), 6511; https://doi.org/10.3390/ijms24076511 - 30 Mar 2023

Cited by 3 | Viewed by 2240

Abstract

Cardiovascular complications combined with COVID-19 (SARS-CoV-2) lead to a poor prognosis in patients. The common pathogenesis of ischemic cardiomyopathy (ICM) and COVID-19 is still unclear. Here, we explored potential molecular mechanisms and biomarkers for ICM and COVID-19. Common differentially expressed genes (DEGs) of ICM (GSE5406) and COVID-19 (GSE164805) were identified using GEO2R. We performed enrichment and protein–protein interaction analyses and screened key genes. To confirm the diagnostic performance for these hub genes, we used external datasets (GSE116250 and GSE211979) and plotted ROC curves. Transcription factor and microRNA regulatory networks were constructed for the validated hub genes. Finally, drug prediction and molecular docking validation were performed using cMAP. We identified 81 common DEGs, many of which were enriched in terms of their relation to angiogenesis. Three DEGs were identified as key hub genes (HSP90AA1, HSPA9, and SRSF1) in the protein–protein interaction analysis. These hub genes had high diagnostic performance in the four datasets (AUC > 0.7). Mir-16-5p and KLF9 transcription factor co-regulated these hub genes. The drugs vindesine and ON-01910 showed good binding performance to the hub genes. We identified HSP90AA1, HSPA9, and SRSF1 as markers for the co-pathogenesis of ICM and COVID-19, and showed that co-pathogenesis of ICM and COVID-19 may be related to angiogenesis. Vindesine and ON-01910 were predicted as potential therapeutic agents. Our findings will contribute to a deeper understanding of the comorbidity of ICM with COVID-19. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Figure 1

Review

Jump to: Research

17 pages, 786 KiB

Open AccessReview

Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL–Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients

by Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi, Radu Andy Sascău and Cristian Stătescu

Int. J. Mol. Sci. 2023, 24(18), 14378; https://doi.org/10.3390/ijms241814378 - 21 Sep 2023

Cited by 43 | Viewed by 4509

Abstract

Cardiovascular disease, particularly coronary artery disease (CAD), remains a predominant cause of mortality globally. Factors such as atherosclerosis and inflammation play significant roles in the pathogenesis of CAD. The nexus between inflammation and CAD is underscored by the role of immune cells, such as neutrophils, lymphocytes, monocytes, and macrophages. These cells orchestrate the inflammatory process, a core component in the initiation and progression of atherosclerosis. The activation of these pathways and the subsequent lipid, fibrous element, and calcification accumulation can result in vessel narrowing. Hematological parameters derived from routine blood tests offer insights into the underlying inflammatory state. Recent studies have highlighted the potential of inflammatory hematological ratios, such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, monocyte/lymphocyte ratio and lymphocyte/monocyte ratio. These parameters are not only accessible and cost-effective but also mirror the degree of systemic inflammation. Several studies have indicated a correlation between these markers and the severity, prognosis, and presence of CAD. Despite the burgeoning interest in the relationship between inflammatory markers and CAD, there remains a paucity of data exploring these parameters in young patients with acute myocardial infarction. Such data could offer valuable insights into the unique pathophysiology of early-onset CAD and improve risk assessment and predictive strategies. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Figure 1

17 pages, 1053 KiB

Open AccessReview

Lipid Biomarkers and Atherosclerosis—Old and New in Cardiovascular Risk in Childhood

by Mirjam Močnik and Nataša Marčun Varda

Int. J. Mol. Sci. 2023, 24(3), 2237; https://doi.org/10.3390/ijms24032237 - 23 Jan 2023

Cited by 12 | Viewed by 4047

Abstract

Lipids are a complex group of molecules in the body, essential as structural, functional and metabolic components. When disbalanced, they are regarded as a cardiovascular risk factor, traditionally in cholesterol level evaluation. However, due to their complex nature, much research is still needed for a comprehensive understanding of their role in atherosclerosis, especially in the young. Several new lipid biomarkers are emerging, some already researched to a point, such as lipoproteins and apolipoproteins. Other lipid molecules are also being increasingly researched, including oxidized forms due to oxidative inflammation in atherosclerosis, and sphingolipids. For many, even those less new, the atherogenic potential is not clear and no clinical recommendations are in place to aid the clinician in using them in everyday clinical practice. Moreover, lipids’ involvement in atherogenesis in children has yet to be elucidated. This review summarizes the current knowledge on lipids as biomarkers of cardiovascular risk in the paediatric population. Full article

(This article belongs to the Special Issue Molecular Biomarkers in Cardiovascular Disease)

► Show Figures

Journal Menu

Journal Browser

Molecular Biomarkers in Cardiovascular Disease

Share This Special Issue

Special Issue Editors

Special Issue Information

Benefits of Publishing in a Special Issue

Published Papers (6 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI